Patent intelligence · PH
PH 12016500580
CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
Patent details — PH 12016500580
- Jurisdiction
- PH
- Status
- granted
- Grant date
- May 30, 2016
- Expiration
- May 25, 2036
- Applicant
- OXFORD BIOTHERAPEUTICS LTD [GB]
- CPC classes
- A61K 39/ 00 A I, A61K/4768, A61K/4768033, A61K/476849
Quick answer
PH 12016500580 (CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER) is held by OXFORD BIOTHERAPEUTICS LTD [GB]. Status: granted. Granted May 30, 2016. Expires May 25, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- OXFORD BIOTHERAPEUTICS LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I, A61K/4768, A61K/4768033, A61K/476849, A61K/476851, A61K/476855
More from OXFORD BIOTHERAPEUTICS LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
WO 2024252263
COMPOSITIONS SOLIDES DE DICHLORHYDRATE D'ÉLACESTRANT, LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT LES UTILISANT
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 2021015826
ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
granted -
US 2020040086
PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 12016500580?
PH 12016500580 (CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER) is held by OXFORD BIOTHERAPEUTICS LTD [GB]. Status: granted. Granted May 30, 2016. Expires May 25, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns PH 12016500580?
OXFORD BIOTHERAPEUTICS LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does PH 12016500580 expire?
Our index shows an expiration date of May 25, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.